Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag with IST for HAAA and SAA with Liver Dysfunction
NCT05571332Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of avatrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Complete Response Rate at 12 weeks and Incidence of Treatment-Emergent Adverse Events at 12 weeks. Status: unknown.
02
Drugs
avatrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05571332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571332.